OOIR: Observatory of International Research

Papers

(The TQCC of Medicinal Research Reviews is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-09-01 to 2023-09-01.)

Article	Citations
Machine intelligence in peptide therapeutics: A next‐generation tool for rapid disease screening	165
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications	137
The role of hypoxia‐inducible factor 1 in tumor immune evasion	129
Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress‐ and aging‐related diseases	118
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)	118
Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention	107
Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules	104
Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?	104
Molecular targeting therapies for neuroblastoma: Progress and challenges	95
A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies	88
Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation	88
Small molecules regulating reactive oxygen species homeostasis for cancer therapy	85
Biologically active isoquinoline alkaloids covering 2014–2018	84
Understanding the tumor microenvironment for effective immunotherapy	84
Tripterygium wilfordii: An inspiring resource for rheumatoid arthritis treatment	79
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions	75
Mechanisms of melanocyte death in vitiligo	75
Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy	74
Therapeutic potential of phenylethanoid glycosides: A systematic review	69
Bilirubin as a signaling molecule	68
Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure‐activity relationship	67
Design and synthesis of glycomimetics: Recent advances	67
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology	66
Flavonoids as antiobesity agents: A review	63
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases	62

Inducible nitric oxide synthase inhibitors: A comprehensive update	61
Emerging carrier‐free nanosystems based on molecular self‐assembly of pure drugs for cancer therapy	61
What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design	60
Bioactive polymeric scaffolds for osteogenic repair and bone regenerative medicine	57
Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation	57
COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays	56
Phytochemistry and cardiovascular protective effects of Huang‐Qi (Astragali Radix)	56
A review in radiomics: Making personalized medicine a reality via routine imaging	56
Medicinal chemistry strategies toward host targeting antiviral agents	55
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases	54
Autophagy and cardiac diseases: Therapeutic potential of natural products	54
Emerging roles of SIRT6 in human diseases and its modulators	53
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy	52
Emerging use of senolytics and senomorphics against aging and chronic diseases	51
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing	50
The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future	47
Skp2 in the ubiquitin‐proteasome system: A comprehensive review	46
Targeting MDM2 for novel molecular therapy: Beyond oncology	46
Development of anti‐influenza agents from natural products	44
Direct targeting of β‐catenin in the Wnt signaling pathway: Current progress and perspectives	43
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review	43
Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug‐resistant Plasmodium falciparum	43
Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections	43
Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas	42
Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy	41
Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer	41
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications	41
Repurposing approved drugs on the pathway to novel therapies	40
Carbon monoxide: An emerging therapy for acute kidney injury	39
Biologically active indolizidine alkaloids	38
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases	38
Principles and current strategies targeting metallo‐β‐lactamase mediated antibacterial resistance	37
A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation	35
Hepcidin and its therapeutic potential in neurodegenerative disorders	34
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition	34
Therapeutic strategies for targeting telomerase in cancer	34
Pattern recognition receptor‐mediated inflammation in diabetic vascular complications	34
The aryl hydrocarbon receptor (AhR) as a breast cancer drug target	34
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism	33
Artemisinin‐derived antimalarial endoperoxides from bench‐side to bed‐side: Chronological advancements and future challenges	33
Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles	33
Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone‐methide triterpenoid celastrol	33
Targeting telomerase for its advent in cancer therapeutics	32
Cistanches Herba, from an endangered species to a big brand of Chinese medicine	32
Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence	32
Expert insights: The potential role of the gut microbiome‐bile acid‐brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy	32
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use	31
Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics	31
Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease	31
Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets	31

The mitochondrial permeability transition pore in cell death: A promising drug binding bioarchitecture	30
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities	30
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer	29
Targeting B7‐1 in immunotherapy	29
The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies	29
Cardiac efficacy and toxicity of aconitine: A new frontier for the ancient poison	28
Strategies for designing proteolysis targeting chimaeras (PROTACs)	28
SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy	28
New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others	28
Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery	28
The role of carbon monoxide, heme oxygenase 1, and the Nrf2 transcription factor in the modulation of chronic pain and their interactions with opioids and cannabinoids	27
The Yin and Yang of traditional Chinese and Western medicine	27
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era	27
Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment	27
Drug design targeting active posttranslational modification protein isoforms	26
Recent progress and new perspectives for diterpenoid biosynthesis in medicinal plants	25
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications	25
Recent advances with 5‐HT₃ modulators for neuropsychiatric and gastrointestinal disorders	25